

KIMIABL/COMP/BSE/24-25/027

Date: 14.08.2024

To,
Corporate Relationship Department
BSE Limited
P.J. Towers
1st Floor, New Trading Ring
Dalal Street, Mumbai- 400001.

Ref: BSE Scrip Code: 530313 and Scrip ID: KIMIABL
Sub: Outcome of Board Meeting

Dear Sir/ Madam,

The meeting of the Board of Directors was held on Wednesday, August 14, 2024 at 3:00 pm (IST), and the following businesses, amongst others, were transacted thereat:

1. Approval of un-audited financial results, on standalone basis, of the Company for the quarter and three months ended June 30, 2024 in accordance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and taking on record the Limited Review Report of the Auditors on the same (copy attached as Annexure A).
2. To take on record the resignation of Mr Lakshay Prakash as Company Secretary & Compliance Officer of the Company.
3. Re-Appointment of Cost Auditor, Mahesh Singh for the financial year 2024-25.


You are requested to take the above information on record and disseminate the same on your website.

The meeting concluded at ..9:10pm

p.m.

Thanking you.

Yours faithfully,
For Kimia Biosciences Limited


Sameer Goel
Managing Director & CEO

Place: New Delhi

KIMIA BIOSCIENCES LIMITED

Regd. Office/Works
Village Bhondsi, Damdama Lake Road,
Gurugram, Haryana -122102
Tel.: +91 9654746544, 9654206544

1/3

Corporate Office
974, 9th Floor, Aggarwal Millenium Tower-II
Netaji Subhash Place, Pitampura, New Delhi-110034, INDIA
Tel: +91 11 47063600, 470630601

compliance.kimia@gmail.com | info@kimiabiosciences.com | www.kimiabiosciences.com | CIN No.: L24239HR1993PLC032120

KIMIA BIOSCIENCES LIMITED

Regd. Office : Village Bhondsi, Tehsil Sohna, Dist. Gurgaon , Haryana - 122102

Phone : +91 9654746544, 9654206544 Email: compliance.kimia@gmail.com & info@kimiabiosciences.com

Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120


UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2024

S. No.	Particulars	Quarter ended			Year Ended
		30/06/2024	31/03/2024	30/06/2023	31/03/2024
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
I	Revenue from Operations	2,239.93	3,030.17	2,423.01	10,487.65
II	Other Income	8.33	30.29	12.52	164.18
III	Total Income (I+II)	2,248.26	3,060.46	2,435.53	10,651.83
IV	Expenses:				
	a) Cost of materials consumed	1,497.22	1,856.31	1,890.92	6,735.80
	b) Change in inventories of finished goods and work-in-progress	(274.57)	79.64	(101.67)	789.73
	c) Employee benefits expenses	342.83	343.83	398.70	1,515.25
	d) Finance costs	110.84	134.36	127.58	504.98
	e) Depreciation and amortisation expense	89.78	81.83	83.21	329.23
	f) Other expenses	303.96	333.94	398.95	1,495.21
V	Total Expenses (IV)	2,070.06	2,829.91	2,797.69	11,370.20
VI	Profit/(loss) before exceptional items and Tax (III-V)	178.20	230.55	(362.16)	(718.37)
VII	Exceptional Items	-	-	-	-
VI	Profit/(loss) before tax (IV-V)	178.20	230.55	(362.16)	(718.37)
VII	Tax expenses:				
	a) Current Tax	29.74	-	-	-
	b) Deferred Tax charge / (credit)	4.75	51.02	(91.11)	(187.50)
VIII	Profit/(loss) for the period (VI-VII)	143.70	179.53	(271.05)	(530.87)
IX	Other Comprehensive Income				
A.	Items that will not be reclassified to Profit or Loss (Net of Tax)				
	- Remeasurement of defined benefit plans	-	17.69	-	17.69
B.	Items that will be reclassified to Profit or Loss (Net of Tax)				
X	Total Comprehensive Income for the period (VIII+IX)	143.70	197.21	(271.05)	(513.18)
XI	Paid up equity share capital (Face value of Rs.1 per equity share)	473.13	473.13	473.13	473.13
XII	Other Equity				(440.03)
XIII	Earnings per equity share (not annualised)				
	Basic in Rs	0.30	0.38	(0.57)	(1.12)
	Diluted in Rs	0.30	0.38	(0.57)	(1.12)

Other Notes

- The business activity of the Company falls within a single primary business segment viz 'Pharmaceuticals' and hence there is no other reportable segment as per Ind AS 108 'operating segments'.
- The figures for three months ended March 31, 2024 are the balancing figure between audited figures in respect of the full financial year and published year to date figures up to the nine months of the previous financial year. The figures for the previous periods have been regrouped/ rearranged, wherever considered necessary, to confirm current period classifications.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 14, 2024.

FOR KIMIA BIOSCIENCES LIMITED

 Sarveer Goel
(Director)

DIN - 00161786

Date : August 14, 2024

Place : New Delhi



Review Report

To
The Board of Directors
Kimia Biosciences Limited
Village Bhondsi, Tehsil Sohna
Gurgaon Haryana-122102

1. We have reviewed the accompanying statement of unaudited financial results of Kimia Biosciences Limited (the "Company") for the period ended June 30, 2024 (the "Statement"). The statement has been prepared by the company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulation, 2015"), which has been initialled by us for identification purposes. The statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.
3. Review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in accordance with applicable accounting standards prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sunil Suresh & Associates
FRN 011646N

Vinay Sharam
Partner



M. No. 523999
UDIN:- 24523999 BKCGEH5244
Place:- Gurugram
Dated:- August 14, 2024